GlassScriptPhysician profile
Steven I Sayegh
NPI 1356488845
$11,649.49
in general payments reported to CMS, 2019-2025
40 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $1,445 · 2021: $3,110 · 2022: $1,555 · 2023: $1,468 · 2024: $1,463 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,557.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,292.02 | 2021 | |
| Lilly USA, LLC | $1,229.89 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $1,030.87 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.52 | 2019-2025 | Jardiance |
| Abbvie INC. | $655.90 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $636.77 | 2021-2025 | |
| Novo Nordisk INC | $618.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $483.81 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $407.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $300.59 | 2019-2023 | |
| Amgen INC. | $270.20 | 2021-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $240.36 | 2019-2023 | |
| Allergan, INC. | $216.85 | 2019-2020 | |
| Dexcom, INC. | $212.43 | 2021-2025 | Dexcom G6 Transmitter |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.